Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis

Cancer

Volumn 82, Issue 5, 1998, Pages 923-930

  Friedberg, Marc H ^a   Glantz, Michael J ^b   Klempner, Mark S ^a   Cole, Bernard F ^c   Perides, George ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Brain tumor; Carcinomatous meningitis; Cerebrospinal fluid; Matrix metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN METASTASIS; CARCINOMATOUS MENINGITIS; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME SPECIFICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; TUMOR RECURRENCE;

ADULT; AGED; ASTROCYTOMA; BRAIN NEOPLASMS; COLLAGENASES; ENZYME TESTS; FEMALE; GELATINASES; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MENINGEAL NEOPLASMS; MENINGITIS; METALLOENDOPEPTIDASES; MIDDLE AGED; PROGNOSIS;

EID: 0032031654     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980301)82:5<923::AID-CNCR18>3.0.CO;2-2     Document Type: Article

References (65)

1. Levin VA, Sheline GE, Cutin PH. Neoplasms of the central nervous system. In: De Vita VTJ, Hellman S, Rosenberg SA. Cancer principles and practice of oncology. 4th edition. Philadelphia: J. B. Lippincott, 1993:1679-737.
2. Posner JB. Neurologic complications of cancer. Philadelphia: F. A. Davis, 1995.
3. Shapiro WR. Therapy of adult malignant brain tumors: what have the clinical trials taught us? Semin Oncol 1986;13:38-45.
4. Burger PC, Heinz ET, Shibata T, Kleihues P. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 1988;68:698-704.
5. DeArmond SJ, Stowring L, Amar A, Coopersmith P, Dougherty D, Spencer D, et al. Development of a non-selecting, non-perturbing method to study human brain tumor cell invasion in murine brain. J Neurooncol 1994;20:27-34.
6. Hsu S, Cole B, Recht L, Glantz L, Mills P, Lekos A. Frequency and prognostic significance of a positive cerebrospinal fluid (CSF) cytology in patients (pts) with gliomas. Neurology 1997;48:A35.
7. Rosenblum ML, Eisenberg AO, Norman D. Brain tumor invasion: clinical patterns of malignant astrocytoma spread. J Neurosurg 1992;76:383A.
8. De Clerck YA, Alvarez O, Shimada H, Taylor SM, Langley KE. Tissue inhibitors of metalloproteinases: role in tumor progression. Extracellular matrix in the kidney. Contrib Nephrol 1994;107:108-15.
9. Del Maestro RF, Waithilingam IS, McDonald W. Degradation of collagen type IV by C6 astrocytoma cells. J Neurooncol 1995;24:75-81.
10. Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery 1996;39:235-50.
11. Paulus W, Tonn JC. Interactions of glioma cells and extracellular matrix. J Neurooncol 1995;24:87-91.
12. Paulus W, Baur I, Dours-Zimmermann MT, Zimmermann DR. Differential expression of versican isoforms in brain tumors. J Neuropathol Exp Neurol 1996;55:528-33.
13. Bignami A, Dahl D, Gilad VH, Gilad GM. Hyaluronate-binding protein produced by white matter astrocytes: an axonal growth repellent? Exp Neurol 1988;100:253-6.
14. Perides G, Lane WS, Andrews D, Dahl D, Bignami A. Isolation and partial characterization of a glial hyaluronate-binding protein (GHAP). J Biol Chem 1989;264:5981-7.
15. Perides G, Asher RA, Rahemtulla F, Lane WS, Bignami A. Isolation of a large aggregating proteoglycan from human brain. J Biol Chem 1992;267:23883-7.
16. Perris R, Johansson S. Inhibition of neural crest cell migration by aggregating chondroitin sulfate proteoglycans is mediated by their hyaluronan-binding region. Dev Biol 1990; 137:1-12.
17. Yamagata M, Kimata K. Repression of a malignant cell-substratum adhesion phenotype by inhibiting the production of the anti-adhesive proteoglycan, PG-M/versican. J Cell Sci 1994;107:2581-90.
18. Perides G, Asher RA, Lark MW, Lane WS, Robinson RA, Bignami A. Glial hyaluronate-binding protein: a product of metalloproteinase digestion of versican? Biochem J 1995;312: 377-84.
19. Yamamoto M, Mohanam S, Sawaya R, Fuller GN, Seiki M, Sato H, et al. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res 1996;56:384-92.
20. Mikkelsen T, Yan PS, Ho K-L, Sameni M, Loane BF, Rosenblum ML. Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. J Neurosurg 1995;83:285-90.
21. Parsons SL, Watson SA, Brown PD, Collins HM, Steele RJC. Matrix metalloproteinases. Br J Surg 1997;84:160-6.
22. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann Rev Cell Biol 1993;9:541-73.
23. Stetler-Stevenson WG. Matrix metalloproteinase inhibitors. Cancer Ther 1997:241-61.
24. Sato H, Seiki M. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. J Biochem 1996;119:209-15.
25. Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T, et al. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg 1994;81:69-77.
26. Rutka JT, Matsuzawa K, Hubbard SL, Fukuyama K, Becker LE, Stetler-Stevenson W, et al. Expression of TIMP-1, TIMP-2, 72-and 92-kDa type IV collagenase transcripts in human astrocytoma cell lines: correlation with astrocytoma cell invasiveness. Int J Oncol 1995;6:877-84.
27. Nakagawa T, Kubota T, Kabuto M, Sato K, Arai Y, Kodera T. Production of tissue inhibitor of metalloproteinases-1 (TIMP-1) by human astrocytic tumors. Neurol Med Chir (Tokyo) 1995;35:728-31.
28. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992;41:29-34.
29. Glantz MJ, Cole BF, Glantz LK, Mills P, Cobb JL, Lekos A. The meaning of a negative cerebrospinal fluid cytology. Neurology 1996;46:A158.
30. Perides G, Charness ME, Tanner LM, Peter O, Satz N, Steere AC, et al. Matrix metalloproteinases in the cerebrospinal fluid of patients with Lyme neuroborreliosis. J Infect Dis. 1998;177:401-8.
31. Towbin H, Stehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4.
32. Backstrom JR, Miller CA, Tokes ZA. Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: identification of calcium-dependent metalloproteinases from the hippocampus. J Neurochem 1992;58:983-92.
33. Papastoitsis G, Siman R, Scott R, Abraham CR. Identification of a metalloproteinase from Alzheimer's disease brain able to degrade the β-amyloid precursor protein and generate amyloidogenic fragments. Biochemistry 1994;33:192-9.
34. Yamada T, Miyazaki K, Koshikawa N, Takahashi M, Akatsu H, Yamamoto T. Selective localization of gelatinase A, an enzyme degrading β-amyloid protein, in white matter microglia and in Schwann cells. Acta Neuropathol 1995;89:199-203.
35. Backstrom JR, Tokes ZA. The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin. J Neurochem 1995;64:1312-8.
36. Lim GP, Backstrom JR, Cullen MJ, Miller CA, Atkinson RD, Tokes ZA. Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J Neurochem 1996;67:251-9.
37. Rosenberg GA, Dencoff JE, Correa N Jr., Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996;46:1626-32.
38. Goldberg GI, Collier IE, Eisen AZ, Grant GA, Marmer BL, Wilhelm SM. Mosaic structure of the secreted ECM metalloproteases and interaction of the type IV collagenases with inhibitors. In: Birkedal-Hansen H. Matrix metalloproteinases and inhibitors. Stuttgart: Gustav Fischer, 1992:25-50.
39. Moutsiakis D, Mancuso P, Krutzsch H, Stetler-Stevenson W, Zucker S. Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma. Connect Tissue Res 1992;28:213-30.
40. Mansour H, Asher R, Dahl D, Labkovsky B, Perides G, Bignami A. Permissive and nonpermissive reactive astrocytes: immunofluorescence study with antibodies to the glial hyaluronate-binding protein. J Neurosci Res 1990;25:300-11.
41. Alexander CM, Werb Z. Extracellular matrix degradation. In: Hay ED. Cell biology of extracellular matrix. 2nd edition. New York: Plenum Press, 1991:255-302.
42. Ennis WB, Matrisian LM. Matrix-degrading metalloproteinases. J Neurooncol 1994;18:105-9.
43. Nagase H. Matrix metalloproteinases: a mini-review Extracellular matrix in the kidney. Contrib Nephrol 1994;107:85-93.
44. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in tissue remodeling. FASEB J 1991;5:2145-54.
45. Uhm JH, Dooley NP, Villemure JG, Yong VW. Mechanisms of glioma invasion: role of matrix-metalloproteinases. Can J Neurol Sci 1997;24:3-15.
46. Engel G, Hesemeyer K, Auer G, Bäckdahl M, Eriksson E, Linder S. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int J Cancer 1994; 58:830-5.
47. Davies B, Brown PD, East N, Crimmins MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenographs. Cancer Res 1993;53:2087-91.
48. Hamdy FC, Fadlon EJ, Cottam D, Lawry J, Thurrell W, Silcocks PB, et al. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1994;69:177-82.
49. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, et al. Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993; 53:5365-9.
50. Himmelstein BP, Canete-Soler R, Bernhard EJ, Dilks DW, Muschel RJ. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 1994;14:246-58.
51. Kawashima A, Nakanishi I, Tsuchiya H, Roessner A, Ken'ichi O, Okada Y. Expression of matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase) induces by tumor necrosis factor a correlates with metastatic ability in a human osteosarcoma cell line. Virchow Arch 1994;421:547-52.
52. Rouyer N, Wolf C, Chenard MP, Rio MC, Chambon P, Bellocq JP, et al. Stromelysin-3 gene expression in human cancer: an overview. Invasion Metastasis 1994;14:269-75.
53. Rosenberg GA. Matrix metalloproteinases in brain injury. J Neurotrauma 1995;12:833-42.
54. Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990;40:435-8.
55. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid otology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38:51-7.
56. Fishman RA. Cerebrospinal fluid in diseases of the nervous system. 2nd edition. Philadelphia: W. B. Saunders, 1992.
57. Barker FG, Chang SM, Valk PE, Pounds TR, Prados MD. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997;79:115-26.
58. Glantz MJ. Diagnosis of radiation-induced nervous system injury. In: Feldmann E. Current diagnosis in neurology. Philadelphia: Mosby-Year Book, Inc., 1994:146-54.
59. Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Ann Neurol 1992;31:431-6.
60. Schwartz RB, Carvalho PA, Alexander Ed, Loeffler JS, Folkerth R, Holman BL. Radiation necrosis versus high-grade recurrent glioma: differentiation by using dual isotope SPECT using Tl-201 and Tc-99 HMPAO. AJNR Am J Neuroradiol 1991;12:1187-92.
61. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 1993;85:704-10.
62. Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994;4:1463-9.
63. Beattie GJ, Young HA, Smyth JF. Phase 1 study of intra-peritoneal metalloproteinase inhibitor BB-94 in patients with malignant ascites. 8th NCI-EORTC symposium on new drug development, Amsterdam, 1994.
64. Macaulay VM, O'Byrne KJ, Saunders MP, Salisbury A, Long L, Gleeson F, et al. Phase I study of matrix metalloproteinase (MMP) inhibitor batimastat (BB-94) in patients with malignant pleural effusions. Br J Cancer 1995;71(Suppl 24):3-6.
65. Drummond AH, Beckett P, Bone EA, Brown PD, Davis M, Galloway WA, et al. BB-2516: an orally bioavailable matrix metalloproteinase inhibitor with efficacy in animal cancer models. Proc Am Assoc Cancer Res 1995;36:595.